Spots Global Cancer Trial Database for Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve
Official Title: Double-blind, Placebo-controlled, Randomized Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve
Study ID: NCT00225290
Conditions
Interventions
Study Description
Brief Summary: To compare the overall survival of thalidomide- and placebo-treated advanced HCC patients.
Detailed Description:
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Taiwan Cooperative Oncology Group, Taipei, , Taiwan
Contact Details
Name: Li-Tzong Chen, M.D Ph.D.
Affiliation: Division of Cancer Research, National Health Research Institute Ward 191
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
